# Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

> **NCT05472220** · PHASE1 · WITHDRAWN · sponsor: **Pamela Munster**

## Conditions studied

- Solid Tumors, Adult
- PIK3CA Mutation-Related Tumors
- PIK3CA Mutation
- Human Papillomavirus-Related Carcinoma
- HPV-Related Squamous Cell Carcinoma
- Human Papillomavirus-Related Squamous Cell Carcinoma
- Locally Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm

## Interventions

- **DRUG:** Alpelisib
- **DRUG:** Carboplatin
- **DRUG:** Hyperpolarized Carbon-13 (13C) Pyruvate
- **DEVICE:** Continuous Glucose Monitor (CGM)

## Key facts

- **NCT ID:** NCT05472220
- **Lead sponsor:** Pamela Munster
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-01
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor funding
- **Last updated:** 2022-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05472220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05472220, "Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05472220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*